Genetics of phase I enzymes

Yu, Aiming

We noted you are experiencing viewing problems

Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems.
No luck yet? More tips for troubleshooting viewing issues
Contact HST Support access@hstalks.com

Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
For additional help, please don't hesitate to contact HST support access@hstalks.com

We hope you have enjoyed this limited-length demo

Request free trial
Recommend to your librarian

Share
Share This Talk
Messaging

Outlook

Gmail

Yahoo!

WhatsApp
Social

Facebook

X

LinkedIn

VKontakte
Permalink
Replay Talk

This is a limited length demo talk; you may login or review methods of obtaining more access.

Slides
Topics
Links
Citation

Printable Handouts

PDF

Navigable Slide Index

Introduction
Outline
Inter-patient variations in drug therapy
Variations in phase I metabolism
Causes of inter-patient variations
Phase I drug-metabolizing enzymes
Genetics of human CYP enzymes
Genetic polymorphism of CYP enzymes
Clinically important human phase I CYP isozymes
CYP2C19 pharmacogenetics
Psychotropic drugs metabolized by CYP2D6
Human CYP2D gene cluster
CYP2D6 genetic variants
Debrisoquine and CYP2D6 genetic polymorphism
Nortriptyline: an excellent example
Fluoxetine N-demethylation by CYP2D6 isoforms
CYP2D6 polymorphism: inter-ethnic difference
Debrisoquine phenotype: inter-ethnic difference
CYP2D6 polymorphism and drug inactivation
CYP2D6 polymorphism and prodrug activation
Metabolism of codeine
Morphine production in CYP2D6 EMs and PMs
Pain tolerance in CYP2D6 EMs and PMs
Codeine intoxication associated with CYP2D6 UM
CYP2D6 is expressed in human brain
CYP genetic polymorphism: issues
CYP genetic polymorphism: opportunity
Phenotyping towards individualized drug therapy
Genotyping towards individualized drug therapy
CYP2D6 genotyping towards individualized therapy
Genotyping/phenotyping methods: comparison
Phenotyping vs. genotyping: pros and cons
Potency of CYP2D6 inhibitor
Drug-drug interactions altered CYP2D6 activity
CYP2D6 polymorphism: psychopharmacotherapy
References

Topics Covered

Inter-patient variations caused by Phase I drug metabolizing enzymes
Genetic polymorphism of CYP2D6 and impact on psychopharmacotherapy
Metabolism, pharmacokinetics, pharmacodynamics and toxicity
Pharmacogenetics and pharmacogenomics move towards individualized drug therapy

Links

Series:

Psychopharmacogenetics

Categories:

Talk Citation

Yu, A. (2007, October 1). Genetics of phase I enzymes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 29, 2025, from https://doi.org/10.69645/HEZV1564.
Export Citation (RIS)